NEW YORK – Software company Hygea Precision Medicine and molecular diagnostic firm Admera Health announced Tuesday a partnership to offer Admera's tests.
San Francisco-based Hygea's software platform helps physicians manage and order genetic testing for patients and communicate with patients about their treatment plans. The platform will be used to offer Admera's PGxOne Plus pharmacogenomic test.
Financial and other terms of the deal were not disclosed.
South Plainfield, New Jersey-based Admera's 50-gene test uses next-generation sequencing to predict how patients will respond to drug therapy in cardiology, psychiatry, pain management, and oncology. The test received approval from the New York State Clinical Laboratory Evaluation Program in 2016.